Cantor Fitzgerald Reiterates Neutral Rating for Humana (NYSE:HUM)

Humana (NYSE:HUM)‘s stock had its “neutral” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $290.00 price objective on the insurance provider’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 14.66% from the company’s current price. Cantor Fitzgerald also issued estimates for Humana’s FY2025 earnings at $16.27 EPS.

Several other equities analysts have also weighed in on HUM. Truist Financial increased their price objective on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. TD Cowen increased their price target on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Morgan Stanley decreased their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research note on Wednesday. Wells Fargo & Company dropped their price objective on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Finally, Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and raised their target price for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Humana currently has an average rating of “Hold” and a consensus price target of $293.05.

Humana Stock Down 2.7 %

NYSE HUM opened at $252.92 on Wednesday. The stock has a market capitalization of $30.45 billion, a P/E ratio of 22.40, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56. Humana has a 52 week low of $213.31 and a 52 week high of $406.46. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a fifty day moving average of $272.44 and a 200-day moving average of $295.47.

Humana (NYSE:HUM) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, equities research analysts forecast that Humana will post 16.11 EPS for the current year.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On Humana

Institutional investors have recently bought and sold shares of the company. Pinnacle Wealth Management Advisory Group LLC raised its holdings in shares of Humana by 3.6% in the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock valued at $272,000 after purchasing an additional 37 shares during the last quarter. Atlas Brown Inc. grew its position in Humana by 0.6% in the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after purchasing an additional 38 shares in the last quarter. Moors & Cabot Inc. increased its stake in Humana by 2.5% in the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after buying an additional 40 shares during the last quarter. Mather Group LLC. lifted its position in Humana by 21.0% during the 4th quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock worth $60,000 after buying an additional 41 shares in the last quarter. Finally, Capital Advisors Ltd. LLC boosted its stake in shares of Humana by 26.1% during the 4th quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider’s stock worth $53,000 after buying an additional 43 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.